What's new? Log in Free sign up

CEL-SCI (CVM)

Company Profile

Company profile

Ticker

CVM

Exchange

Website

CEO

Mr. Geert R. Kersten Esq.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Biological Products, (No Diagnostic Substances)

Biomotion Sciences Ordinary Shares • Amgen • American National • Gilead Sciences • Biogen • Qiagen • Moderna • Bio-Techne • Acorda Therapeutics • BioNTech SE ...

Former names

AURORA CORP, EnerJex Resources, Inc., MILLENIUM PLASTICS CORP, MILLENNIUM PLASTICS CORP

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

840916344

CVM stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Departure of Directors or Certain Officers

Notice of effectiveness

Shelf registration (amended)

30 Oct 24

Shelf registration

Prospectus update (post-effective amendment)

Withdrawal of amendment

Shelf registration (amended)

Registration of securities for employees

Latest ownership filings

View all

PATRICIA B PRICHEP

GEERT R KERSTEN

PATRICIA B PRICHEP

GEERT R KERSTEN

Robert Eugene Watson

PATRICIA B PRICHEP

GEERT R KERSTEN

Financial summary

Financial statements Chart CVM financial data

Quarter (USD)	Jun 24	Dec 23	Sep 23	Jun 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Sep 23	Sep 22	Sep 21	Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	384.65 k	384.65 k	384.65 k	384.65 k	384.65 k	384.65 k
Cash burn (monthly)	952.26 k	805.14 k	2.22 mm	2.40 mm	(no burn)	1.29 mm
Cash used (since last report)	5.51 mm	4.66 mm	12.88 mm	13.90 mm	n/a	7.48 mm
Cash remaining	-5.13 mm	-4.28 mm	-12.49 mm	-13.52 mm	n/a	-7.09 mm
Runway (months of cash)	-5.4	-5.3	-5.6	-5.6	n/a	-5.5

Beta Read what these cash burn values mean

Financial data from CEL-SCI earnings reports.

Institutional ownership, Q2 2024

CVM institutional ownership history Ownership history

2.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	37	65	-43.1%
Opened positions	8	17	-52.9%
Closed positions	36	12	+200.0%
Increased positions	8	13	-38.5%
Reduced positions	8	11	-27.3%

13F shares	Current	Prev Q	Change
Total value	1.26 bn	12.71 bn	-90.1%
Total shares	1.14 mm	6.95 mm	-83.6%
Total puts	147.70 k	108.80 k	+35.8%
Total calls	16.60 k	11.20 k	+48.2%
Total put/call ratio	8.9	9.7	-8.4%

Largest owners	Shares	Value	Change
STT State Street	193.51 k	$224.47 mm	-0.3%
Bridgeway Capital Management	118.30 k	$137.23 mm	-22.1%
Cutter & CO Brokerage	108.45 k	$125.80 mm	+29.4%
Susquehanna International	97.90 k	$113.57 mm	-85.4%
Two Sigma Investments	87.03 k	$100.95 mm	-45.4%
D. E. Shaw & Co.	53.22 k	$61.73 mm	NEW
Millennium Management	50.64 k	$58.74 mm	NEW
Sheets Smith Wealth Management	40.00 k	$46.40 mm	+100.0%
Citadel Advisors	36.47 k	$42.31 mm	NEW
D.a. Davidson & Co.	32.80 k	$38.05 mm	+1.5%

Largest transactions	Shares	Bought/sold	Change
Vanguard	0.00	-2.19 mm	EXIT
CVI	0.00	-878.77 k	EXIT
BLK BlackRock	0.00	-763.44 k	EXIT
Susquehanna International	97.90 k	-571.09 k	-85.4%
Geode Capital Management	0.00	-464.41 k	EXIT
Advisor	0.00	-308.18 k	EXIT
Renaissance Technologies	0.00	-133.80 k	EXIT
NTRS Northern Trust	0.00	-118.38 k	EXIT
LNC Lincoln National	0.00	-115.25 k	EXIT
Two Sigma Investments	87.03 k	-72.47 k	-45.4%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CVM insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
30 Sep 24	Talor Eyal	Common Stock	Grant	Acquire A	No	No	1.06	2,264	2.40 k	118,596
30 Sep 24	Prichep Patricia B	Common Stock	Grant	Acquire A	No	No	1.06	4,047	4.29 k	240,071
30 Sep 24	Kersten Geert R	Common Stock	Grant	Acquire A	No	No	1.06	4,882	5.17 k	1,204,652
28 Jun 24	Kersten Geert R	Common Stock	Grant	Acquire A	No	No	1.16	4,461	5.17 k	1,199,770
28 Jun 24	Prichep Patricia B	Common Stock	Grant	Acquire A	No	No	1.16	3,698	4.29 k	236,024

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

CEL-SCI Announced Multikine Demonstrates Tumor Regression Pre-Surgery In 3 Weeks; FDA Approves 212-Person Study With 73% Survival Rate Vs. 45% Control In Head And Neck Cancer

Multikine is the first cancer immunotherapy to show pre-surgical tumor regression in head and neck cancer in just 3 weeks - confirmed by pathology at surgeryFactors supporting the go-ahead for the 212-person registration

Watching CEL-SCI; Zacks Small-Cap Research Gives Stock $7 Price Valuation

https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_12092024_CVM_Vandermosten.pdf

CEL-SCI Announces The Potential Impact On The Clinical Development Of Its Immunotherapy Multikine Resulting From A Recent U.S. FDA Oncologic Drugs Advisory Committee Meeting; Multikine Has Shown Survival Benefit And Favorable Safety Profile In A Randomized Controlled Phase 3 Study Of Treatment Naïve Resectable Locally Advanced Head And Neck Cancer Patients With Low PD-L1 Expression

Oncologic Drugs Advisory Committee (ODAC) determines risks outweigh benefits in some cancers for frontline immune checkpoint inhibitors, including blockbuster drugs such as Keytruda and Opdivo, in patients with low PD-L1

Press releases

From Benzinga Pro

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

Multikine is the first cancer immunotherapy to show pre-surgical tumor regression in head and neck cancer in just 3 weeks - confirmed by pathology at surgery Factors supporting the go-ahead for the 212-person

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

Biomarker used to select patients who are more likely have favorable outcomes, supporting a successful confirmatory Registration Study Patients with low PD-L1 expression treated with Multikine in the target

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

Oncologic Drugs Advisory Committee (ODAC) determines risks outweigh benefits in some cancers for frontline immune checkpoint inhibitors, including blockbuster drugs such as Keytruda and Opdivo, in patients with low

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.